Emerging Lp(a) Therapies: Mechanisms & Impact on Atherosclerotic CVD

How novel therapies target atherogenic Lp(a) particle

Physicians at the Heart in Diabetes CME Conference in Philadelphia highlighted advances in therapies targeting atherogenic lipoprotein(a) (Lp(a)) particles, which are strongly associated with atherosclerotic cardiovascular disease (CVD). According to Steven E. Nissen, several therapies now in late-phase trials aim to reduce Lp(a) levels through novel mechanisms, potentially reshaping CVD prevention strategies.

Key Clinical Takeaways:

• Lp(a) particles contribute to atherosclerosis via oxidative stress and inflammation, independent of LDL cholesterol.

• New therapies use antisense oligonucleotides or RNA interference to suppress Lp(a) synthesis in the liver.

• Clinical trials report substantial reductions in Lp(a) levels, but long-term safety and cost remain concerns.

Despite widespread awareness of cholesterol’s role in CVD, Lp(a) remains a critical but underaddressed risk factor. A 2024 meta-analysis in The Lancet found that elevated Lp(a) levels (≥50 mg/dL) correlate with a 2.3-fold increased risk of myocardial infarction, even in patients with normal LDL levels. This gap in risk stratification has driven innovation in targeted therapies.

Nissen emphasized that current Lp(a)-lowering drugs, such as pelacarsen (Ionis Pharmaceuticals) and volanesorsen (Sanofi), operate through distinct mechanisms. Pelacarsen, an antisense oligonucleotide, reduces hepatic production of apolipoprotein(a), the protein component of Lp(a). A Phase II trial published in JAMA reported a significant reduction in Lp(a) levels at 12 weeks, with no major adverse events. However, the study’s sample size of 218 participants limits generalizability.

Sanofi’s volanesorsen, an RNA interference therapy, targets the liver’s production of triglyceride-rich lipoproteins, indirectly lowering Lp(a). A 2025 PubMed study involving patients showed a marked reduction in Lp(a) over 16 weeks, though gastrointestinal side effects were noted in some participants. Both therapies are now in Phase III trials, with results expected by 2027.

Funding transparency is critical in evaluating these therapies. Pelacarsen received significant funding from Ionis Pharmaceuticals, while volanesorsen was developed with support from Sanofi’s internal research division. Independent oversight by the FDA and EMA requires rigorous safety monitoring, particularly given Lp(a)’s complex role in lipid metabolism.

The clinical implications extend beyond individual treatment. A 2026 WHO report highlights that Lp(a) testing is underutilized in primary care, with only a small percentage of U.S. physicians routinely measuring it. Integrating Lp(a) screening into standard cardiovascular risk assessments could improve early intervention, though current guidelines from the American Heart Association (AHA) do not yet mandate it.

For healthcare providers, the emergence of Lp(a)-targeted therapies demands updated protocols.

The path forward hinges on resolving key questions: How do these therapies interact with existing CVD medications? What are the long-term risks of sustained Lp(a) suppression? And how can equitable access be ensured? As Phase III trials progress, the medical community awaits data that could redefine cardiovascular care.

For patients and providers navigating these developments, the next step is to engage with a qualified healthcare provider for personalized risk assessments and treatment planning. Early adoption of Lp(a)-lowering strategies may offer significant benefits, but careful evaluation remains essential.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.